Choline Supplementation and Cardiovascular Risk: Evidence Summary
Your healthcare service's assessment is largely accurate—high-dose choline supplementation carries potential cardiovascular risks through TMAO production, and the evidence on cardiovascular outcomes remains mixed, with recent data showing increased mortality risk at high doses.
Cardiovascular Disease Risk: The TMAO Concern
The most significant cardiovascular concern with choline supplementation relates to its gut microbiome-mediated conversion to trimethylamine N-oxide (TMAO). The 2022 ESPEN guidelines explicitly warn that choline (along with L-carnitine and betaine) can be converted by gut microflora into TMAO, "with a potential negative long-term impact on cardiovascular health" 1.
Recent Mortality Data
Most concerning is a 2024 systematic review and meta-analysis showing that each 100 mg/day increase in dietary choline intake was associated with a 6% increased risk of all-cause mortality and an 11% increased risk of cardiovascular disease mortality 2. This represents the highest-quality recent evidence directly addressing mortality outcomes.
Mechanistic Studies Support Harm
Multiple recent animal studies demonstrate that high choline intake causes:
- Cardiac dysfunction, fibrosis, and inflammation in heart failure models 3
- Exacerbation of cardiac dysfunction in hypertensive heart disease through inhibition of endogenous hydrogen sulfide production 4
- Activation of inflammatory pathways (cGAS-STING-NLRP3 inflammasome) leading to cardiac dysfunction 5
These mechanistic findings provide biological plausibility for the observed mortality associations.
Emerging Nuance: TMAO as Marker vs. Cause
Very recent 2025-2026 research challenges the simplistic view of TMAO as purely harmful 6. Some experts now position TMAO as potentially a marker of renal function rather than a direct cardiovascular toxin. Additionally, a 2026 study found that egg-derived phosphatidylcholine supplementation (up to 3.0 g/day for 12 weeks) did not raise TMAO to clinically concerning levels in healthy middle-aged adults 7. However, a 2025 study confirmed that circulating total choline and phosphatidylcholine were positively associated with incident heart failure risk (HR: 1.08 per SD increase), independent of genetic susceptibility 8.
Blood Pressure Effects
The ESPEN guidelines confirm that acute ingestion of high-dose choline may provoke hypotension 1. However, this is an acute effect requiring "excessive" doses and is not a therapeutic benefit for blood pressure management.
Toxicity Profile
The established Upper Limit (UL) for adults is 3.5 g/day 1. Side effects at high doses include:
- Fishy body odor (most common)
- Hypotension
- Nausea and vomiting
- Excessive sweating and salivation
- Potential liver toxicity
Recommended Dosing
For general health, the ESPEN guidelines recommend 400-550 mg/day to support lipid metabolism 1. This is far below doses that cause toxicity or significant TMAO elevation.
For specific deficiency states (e.g., home parenteral nutrition with liver steatosis), doses of 550 mg to 2 g/day may be considered 1.
Clinical Bottom Line
Avoid high-dose choline supplementation (>550 mg/day) for cardiovascular health purposes—the mortality data suggests harm rather than benefit. The one potential exception is documented choline deficiency (manifesting as liver steatosis or muscle damage with elevated creatine kinase), where therapeutic doses up to 2 g/day may be warranted under medical supervision 1.
Key Caveats
- The mortality association data comes from observational studies, though the dose-response relationship and mechanistic plausibility strengthen causality
- Individual variation in gut microbiome composition may affect TMAO production
- The field is evolving rapidly, with 2025-2026 data suggesting TMAO's role may be more complex than previously thought
- Dietary choline from food sources at recommended intake levels (400-550 mg/day) appears safe and necessary for normal metabolism